Atherosclerosis as consequence of chronic infection by chlamydia pneumoniae;Arteriosklerose als folge einer chronischen infektion durch chlamydia pneumoniae

Herz

Volumn 23, Issue 3, 1998, Pages 185-192

  Stille, Wolfgang ^a   Dittmann, Rike ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Arteriosclerosis; Atherosclerosis; Chlamydia pneumoniae; Coronary infarction

Indexed keywords

AZITHROMYCIN; BACTERIUM ANTIBODY; C REACTIVE PROTEIN; CLARITHROMYCIN; DOXYCYCLINE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MACROLIDE; ROXITHROMYCIN; TETRACYCLINE;

ARTICLE; ATHEROSCLEROSIS; BACTERIUM DETECTION; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOGENESIS;

EID: 0031979663     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03044604     Document Type: Article

References (61)

1. Allegra L, Blasi F. Chlamydia pneumoniae infection. Milano: Springer, 1995.
2. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA 1973;70:1753-9.
3. Blasi F, Denti F, Erba M, et al. Detection of Chlamydia pneumoniac but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol 1996;34:2766-9.
4. Campbell LA, O'Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995;172:585-8.
5. Cook PJ, Honeybourne D. Chlamydia pneumoniae. J Antimicrob Chemother 1994;34:859-73.
6. Dahlen GH, Boman J, Birgander LS, et al. Lp(a) lipoprotein. IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA Class II genotype in early coronary artery disease. Atherosclerosis 1995;114:165-74.
7. Enzler MJ, Smith TF, Espy M, et al. Inabiltity to detect Chlamydia pneumoniae (TWAR) in human autopsy coronary arteries (CA) by polymerase chain reaction (PCR). 35th ICAAC, San Francisco, Sept 17-20, 1995.abstract LM81.
8. Fong IW, Chin B, Viira E, et al. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997;35:48-52.
9. Friedmann GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction. N Engl J Med 1974;290:1275-8.
10. Fuster V, Badimon L, Badimon J, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.
11. Gaydos CA, Summersgill JT, Sahney NN, et al. Replication of Chlamydia pncumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996;64:1614-20.
12. Godzik KL, O'Brien ER, Wang SK, et al. In vitro susceptibility of human vascular wail cells to infection with Chlamydia pneumoniae. J Clin Microb 1995;33:2411-4.
13. Gounaris TH, Sioula E, Anagnostopoulou M, et al. Chlamydia pneumoniae (CP) antibodies in patients with acute myocardial infarction (AMI). 35th ICAAC, San Francisco, Sept 17-20, 1995. abstract LM75.
14. Grayston JT, Kuo CC, Wang SP, et al. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infection. N Engl J Med 1986;315:161-8.
15. Grayston JT, Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995;92:3397-400.
16. Grayston JT, Kuo CC, Campbel LA, et al. Proposal to create the Chlamydia prieumoniae sp. nov. for Chlamydia TWAR. Intern J System Bacteriol 1989;39:88-90.
17. Grayston JT, Kuo CC, Campbell LA, et al. Chlamydia pneumoniae, strain TWAR and atherosclerosis. Eur Heart J 1993;14:Suppl. K:66-71.
18. Grimm RH, Neaton JD, Ludwig W, for the Multiple Risk Factor Intervention Trial Group. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 1985;254:1932-7.
19. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
20. Gurfinkel E, Bonzovich G, Mautner B, et al. The Roxis pilot study: Roxithromycin in non Q-wave coronary patients. Can we change the course of coronary artery diseases? 20. Int. Congr. Chemotherapy. Sidney, June 29.-July 7, 1997.abstract 3029.
21. Hahn DL, Saikku P, Chlamydia, smoking and heart disease. Ann Intern Med 1992;117:71.
22. Hahn DL, Golubjanikow R. Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscl Thromb 1992;12:945-7.
23. Jackson LA, Wang S-P, Stewart DK, et al. Azithromycin treatment following percutaneous coronary revascularization procedures. A pilot study. 4. JCMASK, Barcelona, 1998.
24. Juvonen J, Laurila A, Juvonen T, et al. Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1997;29:1054-9.
25. Juvonen J, Juvonen T, Laurila A, et al. Immunohistochemical detection of Chlamydia pnoumoniae in abdominal aortic aneurysms. Ann NY Acad Sci 1996;800:236-8.
26. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control-study. Am J Epidemiol 1996;144:537-47.
27. Kuo CC, Shor A, Campbell LA, et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841-9.
28. Kuo CC, Grayston JT, Cambell LA, et al. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci USA 1995;92:6911-4.
29. Linnanmäki E, Leinonen M, Mattila K, et al. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993;87:1130-4.
30. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:412-24.
31. Maass M, Bartels CB, Engel PM, et al. Endovascular presence of viable Chlamydia pneumonia is a common phenomenon in coronary artery disease. J Am Coll Cardiol (in press).
32. Maass M, Bartels C, Krüger S, et al. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomen in atherosclerotic vascular disease. Atherosclerosis (in press).
33. Maass M, Gieffers J. Prominent serological response to Chlamydia pneumoniae in cardiovascular disease. Immunol Infect Dis 1996;6:65-70.
34. Maass M. Die Assoziation von Chlamydia-Pneumoniae-Infekion und Arteriosklcrose. Infektionsepidemiol Forsch RKI Berlin, Sept 1997:1-5.
35. Meade TW. Fibrinogen and cardiovascular disease. J Clin Pathol 1997;50:13-5.
36. Melnick SL, Shahar E, Folsom AR, et al. Past infection by Chlamydia pneumoniae strains TWAR and asymptomatic carotid atherosclerosis. Am J Med 1993;95:499-505.
37. Mendall MA, Carrington D, Strachan D, et al. Chlamydia pneumoniae risk factors for seropositivity and association with coronary heart disease. J Infect 1995;30:121-8.
38. Miettinen H, Lento S, Saikku P, et al. Associaton of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J 1996;17:682-88.
39. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996;27:1555-61.
40. Ong G, Thomas BJ, Mansfield AO, et al. Detection and wide-spread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol 1996;49:102-6.
41. Ouchi K, Fujii B, Kanamoto Y, et al. Detection of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries and large arteries. 35th ICAAC, San Francisco, Sept 17-20, 1995. abstract K37.
42. Paltiel O, Kark JD, Leinonnen M, et al. High prevalence of antibodies to Chlamydia pneumoniae: determinants of IgG and IgA seropositivity among Jerusalem residents. Epidemiol Infect 1995;114:465-73.
43. Patel P, Carrington D, Strachan DP, et al. Fibrinogen: a link between chronic infection and coronary heart disease. Lancet 1994;343;1634-5.
44. Puolakkainen M, Kuo CC, Shor A, et al. Serological response to Chamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol 1993;31:2212-4.
45. Ramirez JA. The Chlamydia Pneumonaiae/Atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 1996;125:979-82.
46. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
47. Ross R. The pathogenesis of atherosclerosis: a perspective of the 1990s. Nature 1993;362:801-9.
48. Saikku P, Mattila K, Nieminen MS, et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infartion. Lancet 1988;29:983-4.
49. Saikku P, Leinonen M, Linnanmöki E, et al. Association of immune complexes containing chlamydial lipopolysaccharied with coronary heart disease. In: Bowie WR, Caldwell HD, Jones RP, et al., eds. Chlamydial infections. Cambridge: Cambridge University Press, 1990:449-52.
50. Saikku P, Wang SO, Kleemola M, et al. An epidemic of mild pneumoniaia due to an unusual strain of Chlamydia psittaci. J Infect Dis 1985;151:832-9.
51. Saikku P. Chronic Chlamydia pneumoniae infections. In: Allegra L, Blasi F, eds. Chlamydia pneumoniae infection. Milano: Springer, 1995:51-64.
52. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial tatty streaks and atheromatous plaque. S Afr Med J 1992;82:158-61.
53. Stary HC. Pathologie der Atherosklerose. In: Schwand P, Richter E, eds. Handbuch der Fettstoffwechselstörungen. Stuttgart: Schattauer, 1995:48-64.
54. Stille W, Just-Nübling G. Argumente für eine Antibiotika-Therapie der Arteriosklerose. Chemother J 1997;6:1-5.
55. Sutter MC. Lessons for atherosclerosis research from tuberculosis and peptic ulcer. Can med Assoc J 1995;152:667-70.
56. Thorn DH, Grayston JT, Siscovick DS, et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992;268:68-72.
57. Thom DH, Wang SP, Steward DK, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. In: Bowie WR, Caldwell HD, Jones RP, et al., eds. Chlamydial infections. Cambridge: Cambridge University Press, 1990:453-6.
58. Ward ME. The immunobiology and immunopathology of chlamydial infection. APMIS 1995;103:769-96.
59. Weiss SM, Boblin PM, Gaydos CA, et al. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996;173:957-62.
60. Yarnell JWG, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerplhilly and Speedwell Heart Disease Studies. Circulation 1991;83:836-44.
61. Zalokar JB, Richard JL, Claude JR. Leukocyte count, smoking, and myocardial infarction. N Engl J Med 1981;304:465-8.